BiotechTube

Ibudilast + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pneumonia, Viral

Conditions

Pneumonia, Viral

Trial Timeline

Jan 11, 2021 → Aug 7, 2024

NCT ID
NCT04429555

About Ibudilast + Placebo

Ibudilast + Placebo is a phase 2 stage product being developed by MediciNova for Pneumonia, Viral. The current trial status is completed. This product is registered under clinical trial identifier NCT04429555. Target conditions include Pneumonia, Viral.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04429555Phase 2Completed

Competing Products

20 competing products in Pneumonia, Viral

See all competitors
ProductCompanyStageHype Score
CAL02 Low-dose + CAL02 High-dose + PlaceboCombioxinPhase 1
25
tacrolimusAstellas PharmaPre-clinical
23
Cefiderocol + Best Available TherapyShionogiPhase 3
77
Cefiderocol + Meropenem + LinezolidShionogiPhase 3
77
Cefiderocol + Standard of Care AntibioticShionogiPhase 1
33
ONO-5046Na + ONO-5046NaOno PharmaceuticalPhase 2
52
doripenemJohnson & JohnsonApproved
85
levofloxacin; imipenem/cilastitinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 3
77
levofloxacinJohnson & JohnsonPhase 2/3
65
LevofloxacinJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
doripenemJohnson & JohnsonPhase 3
77
Doripenem + Imipenem-Cilastatin + PlaceboJohnson & JohnsonPhase 3
77
Imipenem/cilastatin + Imipenem/cilastatin + Doripenem + DoripenemJohnson & JohnsonPhase 2
52
HRS-8427 + MeropenemJiangsu Hengrui MedicinePhase 2
52
Ceftazidime-avibactamAbbViePhase 1
33
Ticagrelor + PlaceboAstraZenecaPhase 2
52
Tedizolid phosphate + LinezolidMerckPhase 3
77
Ceftolozane/Tazobactam + Piperacillin/TazobactamMerckPhase 3
77

Other Products from MediciNova

MN-166 + placeboPhase 2/3
57
Ibudilast + Placebo oral capsulePhase 2
44
MN-166 (50 mg) First + Placebo FirstPhase 2
44
MN-001 + PlaceboPhase 2
44
Dose Group 1 + MN-221 placebo + Dose Group 2 + Dose Group 3Phase 2
44